Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nicotinamide Riboside in Ataxia-Telangiectasia
NCT06324877Not yet recruiting
- Sponsor
- The University of Queensland
- Start
- May 2024
- Primary completion
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of nicotinamide riboside in ataxia-telangiectasia (AT), sponsored by The University of Queensland. Primary endpoints: Scales for Assessment and Rating of Ataxia at 12 months and International Cooperative Ataxia Rating Scale at 12 months. Planned start May 2024; status: not yet recruiting.
02
Drugs
nicotinamide riboside
03
Conditions
ataxia-telangiectasia (AT)
Beyond the preview
Go deeper on NCT06324877.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06324877.